SCHEMBL3673035

SCHEMBL3673035

Clc1ccc(OCc2cn(-c3ccc4[nH]ncc4c3)nn2)c(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 9/20 0.65
JAK2 O60674 9/20 0.57
GSK3B P49841 9/20 0.57
PIM1 P11309 3/20 0.57
AURKB Q96GD4 5/20 0.55
AURKA O14965 3/20 0.55
PRKACA P17612 3/20 0.55
GSK3A P49840 3/20 0.55
RPS6KA3 P51812 3/20 0.55
CDK5 Q00535 3/20 0.55
PRKAA1 Q13131 3/20 0.55
ROCK1 Q13464 3/20 0.55
DYRK1A Q13627 3/20 0.55
CDK1 P06493 2/20 0.55
CDK2 P24941 2/20 0.55
MARK3 P27448 2/20 0.55
MAPK1 P28482 2/20 0.55
PRKCD Q05655 2/20 0.55
CDC42BPA Q5VT25 2/20 0.55
DAPK3 O43293 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3672363 0.83 ROCK2 (0.67) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL3667820 0.80 ROCK2 (0.71) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL3666181 0.79 ROCK2 (1.00) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL4293081 0.73 JAK2 (1.00) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL3670230 0.71 JAK2 (1.00) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL3667547 0.71 JAK2 (1.00) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL3670472 0.70 ROCK2 (0.69) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL4289890 0.70 JAK2 (0.72) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL3665013 0.70 JAK2 (1.00) ROCK2JAK2GSK3BPIM1AURKB
SCHEMBL3664524 0.70 ROCK2 (1.00) ROCK2JAK2GSK3BPIM1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885JAK2 102/4885GSK3B 1/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 ROCK2 48/4885JAK2 102/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.